Videos

Experts weigh EDSS vs patient-reported symptoms in SPMS, urging composite endpoints, MRI insights, and smarter coding to improve therapy access.

The expert pharmacists examined the critical importance of timing in RSV immunization for pregnant individuals and infants, noting that patient conversations often fall at opposite ends of the spectrum, from eager acceptance to strong resistance.

Explore who drives REMS success—from FDA and manufacturers to pharmacists and patients—and how MS therapy routes shape safety, adherence, and workflow.

The second part of this video series highlights thoughts from 4 panelists on shared clinical decision-making and how harmful misinformation is in the health care space.

Consumers seek clinically validated supplements as health information spreads quickly; Niagen Bioscience stresses independent evidence, and pharmacists guide choices using trusted certifications.

Laxmi Mehta, MD, explains how pharmacists can counsel patients on inherited lipid risk factors like lipoprotein(a) and why combining pharmacologic therapy with lifestyle modification is essential for reducing cardiovascular risk.

A group of experts provide insights and answer questions to some of the more pressing topics around changes in vaccine schedules and policies.

Experts discuss practice expansion, guideline updates, and team-based care.

Early electronic health record (EHR) collaboration, scalable clinical infrastructure, and payer strategy planning are essential for pharmacists as cell and gene therapies expand across disease states.

Neoadjuvant pembrolizumab reshapes desmoplastic melanoma care, spotlighting sequence integrity, pharmacist-led toxicity readiness, and oncology networks accelerating rare-cancer immunotherapy innovation.

Wildfire smoke exposure increases asthma morbidity, underscoring the pharmacist’s role in medication preparedness and patient education.

Emerging skin lipid biomarkers precede atopic dermatitis and food allergy, emphasizing barrier restoration as a key therapeutic target for pharmacists.

RSV drives massive U.S. healthcare costs, with hospitalizations fueling most expenses; learn why prevention, vaccines, and antibodies protect adults, infants, and families.

Pharmacist experts explain RSV seasonality, symptoms and high-risk groups, then share practical strategies to close immunization gaps and streamline vaccine delivery.

Remibrutinib is the first oral advanced therapy for adults with chronic spontaneous urticaria (CSU) who remain uncontrolled on high-dose second-generation antihistamines.

Careful history, adherence support, and proper medication technique are central to diagnosing and managing chronic cough in children.

Social determinants of health and environmental exposures during extreme weather events worsen asthma outcomes.

Explore emerging multiple sclerosis treatments, from brain-protective targets and remyelination to CAR-T, stem cell transplants, and more accessible anti-CD20 options.

Experts explore emerging multiple sclerosis treatments, from brain-protective PDE4 inhibitors and remyelination to CAR T, stem cell transplant, and easier anti-CD20 options.

Managing high-cost oncology therapies requires extensive cross-functional coordination, with pharmacists playing a central role.

Comprehensive prevention and cardiometabolic risk control in prediabetes can reduce long-term complications, improve survival, and lower health system burden.

Oncology pharmacists can advocate and communicate clearly to boost recognition, strengthen care teams, and improve cancer treatment outcomes.

Laxmi Mehta, MD, discusses widespread patient unawareness of nonstatin cholesterol therapies, common statin misconceptions, and the critical role pharmacists play in bridging the lipid treatment knowledge gap.

Oncology pharmacists can share advocacy tips, craft elevator pitches, and use virtual Capitol Hill days to boost patient access and cancer care.

Experts Craig Beavers and Kristen Campbell discuss what pharmacists should know heading into ACC 26.

The Role of Clinical Pharmacists – Best Practices and Early Execution

Preventing progression from prediabetes to type 2 diabetes improves patient outcomes while substantially reducing health system greenhouse gas emissions.

Finibrutinib’s phase 3 MS results hint at new hope for relapsing and progressive disease, as experts weigh safety and monitoring.

Why MS relapses aren’t the whole story: experts explain PIRA, the push for remyelination, and how BTK inhibitors may reach the CNS.